Asked by: Paulette Hamilton (Labour - Birmingham, Erdington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on the impact of staffing on the (a) National Cancer Patient Experience Survey programme and (b) collection of data on people with pancreatic cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are not aware of an impact of staffing on the National Cancer Patient Experience Survey programme, or on the collection of data on people with pancreatic cancer.
The Department is working closely with NHS England to make sure we have the right workforce with the right skills, across the country. In 2023, the National Health Service published the first ever Long Term Workforce Plan, backed by over £2.4 billion of Government funding, to deliver the biggest training expansion in NHS history. Regarding cancer specifically, the number of staff in the cancer workforce has increased by 50% since 2010.
The 2022 National Cancer Patient Experience survey showed respondents’ average rating of care was 8.8 out of 10, with zero being very poor and 10 very good. 75.5% of respondents said they definitely received the right amount of support for their overall health and wellbeing from hospital staff.
Mar. 19 2024
Source Page: Meetings with Scottish Fire and Rescue Service and Fire Brigades Union: FOI releaseFound: QUERY (EXPRESS) Pancreatic Cancer UK release below which features a Fife supporting their “Don’t Write
Correspondence Mar. 18 2024
Committee: Health, Social Care and Sport CommitteeFound: Hollywood, VP Hepatology, British Society Gastroenterology Dr Sorcha Hume, Public Affairs Manager, Cancer
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 29 May 2023Found: the skin cancer.
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 27 March 2023Found: There is no preclinical or clinical signal for pancreatitis or pancreatic cancer. 05JT2ZMK-0431A
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: (5), malignant melano ma (3), brain cancer (2), thyro id cancer (2), non -Hodgkin’s lympho ma (2),
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: (breast cancer/cervix neoplasm/co lon cancer/l eukaemia/neoplasm malignant - 7 cases).
Mentions:
1: Lord Oates (LD - Life peer) poignant day for me, as it was on International Women’s Day six years ago that my mother died from pancreatic - Speech Link
Written Evidence Mar. 05 2024
Committee: Health and Social Care Committee (Department: Department of Health and Social Care)Found: cancer.
Asked by: McMillan, Stuart (Scottish National Party - Greenock and Inverclyde)
Question
To ask the Scottish Government whether it will offer free BRCA gene testing to anyone living in Scotland aged 18 or over with one or more Jewish grandparents, of any type of Jewish origin, in a similar way to NHS England's Jewish BRCA Testing Programme, in light of the reported finding that having a BRCA gene fault is associated with an increased risk of developing certain types of cancer, particularly breast, ovarian, prostate and pancreatic cancer.
Answered by Gray, Neil - Cabinet Secretary for NHS Recovery, Health and Social Care
As set out in answer to question S6W-25450 on 27 February 2024, NHS Scotland currently offers a whole gene screening panel for hereditary breast and ovarian cancer to test for faults in both BRCA1 and BRCA2 and a range of other target genes. At present, this testing is available to people from specific population groups (including those of Ashkenazi Jewish heritage) if they meet clinical criteria that indicate a higher genetic risk of breast and ovarian cancer.
The Scottish Strategic Network for Genomic Medicine (SSNGM) was established in 2022 to develop a fully considered and sustainable genomic medicine service for Scotland. The SSNGM contains specialist Scottish Genomics Test Advisory Groups (SG-TAG) for both cancer and rare and inherited conditions, whose role is to review and assess the clinical validity and utility of new tests, and changes to the referral criteria for existing tests.
The SSNGM plan to initiate a review of the existing hereditary cancer testing pathways in 2024. This review will include both the referral criteria for our existing genomic test offering and alternative testing methods and will make recommendations via the SG-TAG process.
All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .